CORE-ABR
Sales sheet Request a demo

Resistance gene

Class B metallo-beta-lactamase (IMP / VIM)

Predicts: Metallo-carbapenemase production. Reported qualitatively as detected or not detected.

Qualitative PCR targetApplied per organism

Mechanism

Zinc-dependent enzymes that hydrolyze nearly all beta-lactams, and are not inhibited by avibactam, vaborbactam or relebactam.

What it removes from the grid

Penicillins, cephalosporins, carbapenems and the newer beta-lactam / inhibitor combinations.

What it spares

Aztreonam is not hydrolyzed by metallo-beta-lactamases — though co-carried enzymes often compromise it.

A multiplex panel can't say which organism in a mixed specimen carries a detected gene. CORE-ABR applies Class B metallo-beta-lactamase (IMP / VIM) only to organisms known to carry it, and only to the agents its mechanism defeats — so a detected gene moves the right cells and spares the rest.

Organisms it is applied to

Pseudomonas aeruginosaA non-fermenting gram-negative bacillus common in chronic wounds and complicated UTI, with a long list of intrinsic resi…Gram-negative bacteria · UTI · Wound · STIAcinetobacter baumanniiA non-fermenting gram-negative bacillus, notorious in healthcare settings for accumulating resistance.Gram-negative bacteria · UTI · Wound · STIKlebsiella pneumoniae / oxytocaCommon uropathogens and a leading host of ESBL and KPC carbapenemase genes.Gram-negative bacteria · UTI · Wound · STIEscherichia coliThe most common cause of urinary tract infection, and a frequent organism in wound and intra-abdominal specimens.Gram-negative bacteria · UTI · WoundEnterobacter aerogenes / cloacaeEnterobacterales with chromosomal AmpC. E. aerogenes has been renamed Klebsiella aerogenes; many panels still report the…Gram-negative bacteria · UTI · Wound · STI

Coding

Z16.19 (resistance to other specified beta lactam antibiotics), as documentation supports. CORE-ABR adds resistance findings as supporting codes, not primary, and prints the rationale on the report.

Tagged

Decision support only. The treating clinician decides. Molecular genotype does not replace phenotypic susceptibility testing, culture, or public-health reporting. Absence of a detected resistance gene does not establish susceptibility. Organism targets vary by panel; CORE-ABR is configured to the assay each laboratory runs.